@article{RolfesBordeMoellenhoffetal.2022, author = {Rolfes, Muriel and Borde, Julika and M{\"o}llenhoff, Kathrin and Kayali, Mohamad and Ernst, Corinna and Gehrig, Andrea and Sutter, Christian and Ramser, Juliane and Niederacher, Dieter and Horv{\´a}th, Judit and Arnold, Norbert and Meindl, Alfons and Auber, Bernd and Rump, Andreas and Wang-Gohrke, Shan and Ritter, Julia and Hentschel, Julia and Thiele, Holger and Altm{\"u}ller, Janine and N{\"u}rnberg, Peter and Rhiem, Kerstin and Engel, Christoph and Wappenschmidt, Barbara and Schmutzler, Rita K. and Hahnen, Eric and Hauke, Jan}, title = {Prevalence of cancer predisposition germline variants in male breast cancer patients: results of the German Consortium for Hereditary Breast and Ovarian Cancer}, series = {Cancers}, volume = {14}, journal = {Cancers}, number = {13}, issn = {2072-6694}, doi = {10.3390/cancers14133292}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-281758}, year = {2022}, abstract = {Male breast cancer (mBC) is associated with a high prevalence of pathogenic variants (PVs) in the BRCA2 gene; however, data regarding other BC predisposition genes are limited. In this retrospective multicenter study, we investigated the prevalence of PVs in BRCA1/2 and 23 non-BRCA1/2 genes using a sample of 614 patients with mBC, recruited through the centers of the German Consortium for Hereditary Breast and Ovarian Cancer. A high proportion of patients with mBC carried PVs in BRCA2 (23.0\%, 142/614) and BRCA1 (4.6\%, 28/614). The prevalence of BRCA1/2 PVs was 11.0\% in patients with mBC without a family history of breast and/or ovarian cancer. Patients with BRCA1/2 PVs did not show an earlier disease onset than those without. The predominant clinical presentation of tumor phenotypes was estrogen receptor (ER)-positive, progesterone receptor (PR)-positive, and HER2-negative (77.7\%); further, 10.2\% of the tumors were triple-positive, and 1.2\% were triple-negative. No association was found between ER/PR/HER2 status and BRCA1/2 PV occurrence. Comparing the prevalence of protein-truncating variants (PTVs) between patients with mBC and control data (ExAC, n = 27,173) revealed significant associations of PTVs in both BRCA1 and BRCA2 with mBC (BRCA1: OR = 17.04, 95\% CI = 10.54-26.82, p < 10\(^{-5}\); BRCA2: OR = 77.71, 95\% CI = 58.71-102.33, p < 10\(^{-5}\)). A case-control investigation of 23 non-BRCA1/2 genes in 340 BRCA1/2-negative patients and ExAC controls revealed significant associations of PTVs in CHEK2, PALB2, and ATM with mBC (CHEK2: OR = 3.78, 95\% CI = 1.59-7.71, p = 0.002; PALB2: OR = 14.77, 95\% CI = 5.02-36.02, p < 10\(^{-5}\); ATM: OR = 3.36, 95\% CI = 0.89-8.96, p = 0.04). Overall, our findings support the benefit of multi-gene panel testing in patients with mBC irrespective of their family history, age at disease onset, and tumor phenotype.}, language = {en} } @article{RitterZimmermannJoehrensetal.2018, author = {Ritter, Julia and Zimmermann, Karin and J{\"o}hrens, Korinna and Mende, Stefanie and Seegebarth, Anke and Siegmund, Britta and Hennig, Steffen and Todorova, Kremena and Rosenwald, Andreas and Daum, Severin and Hummel, Michael and Schumann, Michael}, title = {T-cell repertoires in refractory coeliac disease}, series = {Gut}, volume = {67}, journal = {Gut}, number = {4}, doi = {10.1136/gutjnl-2016-311816}, url = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-226350}, pages = {644-653}, year = {2018}, abstract = {Objective Refractory coeliac disease (RCD) is a potentially hazardous complication of coeliac disease (CD). In contrast to RCD type I, RCD type II is a precursor entity of enteropathy-associated T-cell lymphoma (EATL), which is associated with clonally expanding T-cells that are also found in the sequentially developing EATL. Using high-throughput sequencing (HTS), we aimed to establish the small-intestinal T-cell repertoire (TCR) in CD and RCD to unravel the role of distinct T-cell clonotypes in RCD pathogenesis. Design DNA extracted from duodenal mucosa specimens of controls (n=9), active coeliacs (n=10), coeliacs on a gluten-free diet (n=9), RCD type I (n= 8), RCD type II (n= 8) and unclassified Marsh I cases (n= 3) collected from 2002 to 2013 was examined by TCR beta-complementarity- determining regions 3 (CDR3) multiplex PCR followed by HTS of the amplicons. Results On average, 106 sequence reads per sample were generated consisting of up to 900 individual TCR beta rearrangements. In RCD type II, the most frequent clonotypes (ie, sequence reads with identical CDR3) represent in average 42.6\% of all TCR beta rearrangements, which was significantly higher than in controls (6.8\%; p<0.01) or RCD type I (6.7\%; p<0.01). Repeat endoscopies in individual patients revealed stability of clonotypes for up to several years without clinical symptoms of EATL. Dominant clonotypes identified in individual patients with RCD type II were unique and not related between patients. CD-associated, gliad-independent CDR3 motifs were only detectable at low frequencies. Conclusions TCR beta-HTS analysis unravels the TCR in CD and allows detailed analysis of individual TCR beta rearrangements. Dominant TCR beta sequences identified in patients with RCD type II are unique and not homologous to known gliadin-specific TCR sequences, supporting the assumption that these clonal T-cells expand independent of gluten stimulation.}, language = {en} }